ArriVent BioPharma, Inc. (AVBP) FinancialsAVBPArriVent BioPharma, Inc.

Evaluating the bottom line, ArriVent BioPharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.10%, provide a clear picture of how effectively AVBP converts its operational activities into shareholder value.

In the context of the broader market, AVBP competes directly with industry leaders such as CRON and BRBR. With a market capitalization of $1.46B, it holds a leading position in the sector. When comparing efficiency, AVBP's gross margin of N/A stands against CRON's 53.69% and BRBR's 27.89%. Such benchmarking helps identify whether ArriVent BioPharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a year-to-date change of +45.05% and a one-year change of +52.07%, indicating strong recent performance despite ongoing losses.